211513-15-4

Upstream product

• 3814-34-4 2-ethyl-1-bromobutane 
• 98-89-5 Cyclohexanecarboxylic acid 
• 381209-09-2 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid 
• 211515-46-7 1-(2-ethyl-butyl)-cyclohexanecarbonyl chloride 
• 1141-88-4 2-Aminophenyl disulfide 

Downstream Products

• 211513-21-2 Dalcetrapib 
• 1381883-98-2 2-[1-(2-ethyl-butyl)cyclohexyl]benzothiazole 
• 211513-37-0 dalcetrapib 

Relevant academic research and scientific papers

NOVEL PROCESS

The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is a useful pharmaceutical active compound.

NOVEL PROCESS

The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl] 2-methylthiopropionate which is a useful pharmaceutical active compound.

Bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein

A series of bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, S-(2-(acylamino)-phenyl) alkanethioates, and related compounds were synthesized, and their inhibitory effect on cholesteryl ester transfer protein activity in human plasma was evaluated. This study elucidated the structural requirements for inhibitory activity and determined that the optimum compound was S-(2-((1-(2-ethylbutyl)cyclohexane)carbonylamino)phenyl) 2-methylpropanethioate (27) (JTT-705). This compound achieved 50% inhibition of CETP activity in human plasma at a concentration of 9 μM and 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. It increased the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 or 100 mg/kg once a day for 3 days to male Japanese white rabbits.